article thumbnail

Merck’s Keytruda wins coveted FDA nod around surgery for early lung cancer—with a surprise

Fierce Pharma

Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. The drug's label already includes an overall survival win from a key trial.

FDA 131
article thumbnail

FDA declines Eli Lilly’s bowel disease drug over manufacturing issues

Pharmafile

However, concerns weren’t expressed over the clinical data package, safety or label for the medicine. Mirikizumab was hoped to become a new drug treatment for ulcerative colitis (UC), a condition where abnormal reactions in the immune system cause inflammation in the inner lining of the colon. read more

FDA 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EU probes low platelet safety issue with COVID-19 shots

pharmaphorum

The experts have also recommended a safety update on the label of Oxford University/AstraZeneca’s COVID-19 vaccine, which has been linked to anaphylactic reactions, in what has turned out to be a concerning week for vaccine safety.

Vaccines 145
article thumbnail

AC Immune claims half a win for tau drug in Alzheimer’s trial

pharmaphorum

Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another. AC Immune has a lot riding on the tau hypothesis.

article thumbnail

EU gives narrower label to Apellis, Sobi’s PNH drug

pharmaphorum

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The post EU gives narrower label to Apellis, Sobi’s PNH drug appeared first on.

article thumbnail

Valneva eyes teenage label for chikungunya vaccine in Europe and Canada

Pharmaceutical Technology

A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

article thumbnail

Oral penicillin challenge deemed safe and effective in low-risk allergy patients

Hospital Pharmacy Europe

Removing the label of being allergic to penicillin involves intra-dermal skin testing followed by an oral penicillin challenge. The primary outcome of interest was a physician-verified positive immune-mediated oral penicillin challenge within one hour after the intervention. None of these were deemed to be serious.